Oxymetazoline Hydrochloride Patent Expiration
Oxymetazoline Hydrochloride is used for reducing persistent facial redness associated with rosacea in adult patients. It was first introduced by Bayer Healthcare Llc
Oxymetazoline Hydrochloride Patents
Given below is the list of patents protecting Oxymetazoline Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Upneeq | US10799481 | Compositions and methods for treating ocular disorders | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US10814001 | Oxymetazoline compositions | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US10898573 | Oxymetazoline compositions | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US10940138 | Compositions and methods for treating ocular disorders | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US11103482 | Oxymetazoline compositions | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US11311515 | Oxymetazoline compositions | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US11324722 | Compositions and methods for treating ocular disorders | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US11541036 | Oxymetazoline compositions | Dec 16, 2039 | Rvl Pharms |
| Upneeq | US11701343 | Compositions and methods for treating ocular disorders | Dec 16, 2039 | Rvl Pharms |
| Rhofade | US10335391 | Stabilized oxymetazoline formulations and their uses | Jun 11, 2035 | Mayne Pharma |
| Rhofade | US10751325 | Stabilized oxymetazoline formulations and their uses | Jun 11, 2035 | Mayne Pharma |
| Rhofade | US11517560 | Stabilized oxymetazoline formulations and their uses | Jun 11, 2035 | Mayne Pharma |
| Rhofade | US9974773 | Stabilized oxymetazoline formulations and their uses | Jun 11, 2035 | Mayne Pharma |
| Rhofade | US8883838 | Pharmaceutical cream compositions and methods of use | Dec 01, 2031 | Mayne Pharma |
| Upneeq | US10912765 | Compositions and methods for non-surgical treatment of ptosis | Aug 26, 2031 | Rvl Pharms |
| Upneeq | US8357714 | Compositions and methods for non-surgical treatment of ptosis | Aug 26, 2031 | Rvl Pharms |
| Upneeq | US9867808 | Compositions and methods for non-surgical treatment of Ptosis | Aug 26, 2031 | Rvl Pharms |
| Rhofade | US7812049 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists | May 02, 2028 | Mayne Pharma |
| Rhofade | US8420688 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug 02, 2024
(Expired) | Mayne Pharma |
| Rhofade | US8815929 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan 22, 2024
(Expired) | Mayne Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Oxymetazoline Hydrochloride's patents.
Latest Legal Activities on Oxymetazoline Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Oxymetazoline Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Jul, 2024 | US8357714 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10814001 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10799481 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Feb, 2024 | US10751325 |
| Recordation of Patent eGrant | 18 Jul, 2023 | US11701343 |
| Mail Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
| Electronic Review Critical
| 18 Jul, 2023 | US11701343 |
| Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
| Email Notification Critical
| 18 Jul, 2023 | US11701343 |
| Patent Issue Date Used in PTA Calculation Critical
| 18 Jul, 2023 | US11701343 |
Oxymetazoline Hydrochloride's Family Patents
